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Abstract A~ ~/A4) is the major constituent ofbrain amyloid in Alzheimer's disease (AD), Down's yndrome (DS) and normal aged persons. This 
protein is presumably derived by normal proteolysis from a precursor protein (APP). In this study, C-terminal fragments ofAPP in a Tris/Triton soluble 
fraction were partially purified from DS brain by heparin-affinity and reverse phase chromatography, and analyzed by N-terminal amino acid 
sequencing after SDS polyacrylamide g l electrophoresis and Western blotting. We found at least six different C-terminal fragments including those 
with the entire ,Aft region. These results uggest that secretory processing ofAPP is heterogeneous and generates amyloidogenic C-terminal fragments. 
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1. Introduction 
Aft (fl/A4) is the major constituent of senile plaque and 
cerebrovascular amyloid in Alzheimer's disease (AD), Down's 
syndrome (DS) and normal aged persons [1-3]. This protein is 
thought o be derived by proteolysis from a transmembrane 
glycoprotein precursor, termed APP [2,4,5]. The C-terminal 
one-third of the Aft sequence spans part of the transmembrane 
domain and N-terminal two-thirds extends into the adjacent 
extracellular domain of APP [4]. Secretory forms of APP have 
been detected in brain and cerebrospinal fluid (CSF) [6-8]. In 
previous tudies, APP was found to be cleaved in the interior 
of the Aft sequence, which would preclude amyloid formation 
[9-11]. Recent studies how that an intact Aft is produced in 
soluble form during normal cellular metabolism [12-14] and is 
released into the CSF even in normal subjects [12,13]. One 
possible source of Aft is cell surface APP that has been reinter- 
nalized and metabolized in the lysosome [15,16]. Alternatively, 
intact Aft is also left behind on the amyloidogenic C-terminal 
fragment of APP produced by alternative processing at or near 
the cell surface [7,8,17]. In order to shed light on the origin and 
mechanism of amyloid formation, we are attempting to fully 
characterize the various derivatives of APP in the brain itself. 
We have previously reported that the secretory form of APP- 
695 in human brain and CSF lacks fl/A4 immunoreactivity, 
suggesting alternative processing of APP to leave the entire Aft 
sequence behind on the membrane [7,8]. To confirm this result, 
we have analyzed C-terminal fragments of APP in the mem- 
brane fraction of DS brain. 
2. Materials and methods 
2.1. Isolation of C-terminal fragments 
DS brain cortex (55-year-old female) was homogenized with a teflon- 
glass homogenizer in 9 vol. of 10 mM Tris-HCl, pH 7.5, containing 0.2 
M NaC1, 0.5 mM PMSF and 1 mM EDTA and centrifuged at 
47,400 xg for 60 min. The pellet was rehomogenized and centrifuged 
as before. The pellet was homogenized in 10 mM Tris-HCl, 0.2 M NaCI, 
0.5% Triton X-100, 0.1 mM PMSF, 1 mM EDTA, pH 7.5, and centri- 
fuged again. The supernatant fraction was applied on an Affigel-Hepa- 
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rin (Bio-Rad) column. The unbound fraction was applied on an Aq- 
uapore Prep-10 C-4 (Perkin Elmer) HPLC column and eluted with 60% 
acetonitrile. For further purification, the eluted fraction was adjusted 
to 20% acetonitrile/0.05% TFA. This fraction was applied on a column 
of Bakerbond Wide-Pore C4 (Baker Bond) and eluted with acetonitrile 
(20-75%) in 0.05% TFA. The anti-C-terminal R37 immunoreactive 
fractions were pooled. 
2.2. SDS-polyacrylamide g l electrophoresis (SDS-PAGE) and 
immunoblotting 
Purified APP was analyzed with SDS-PAGE (15 25% gradient 
Laemmli gel and 10-16.5% gradient gel of Tris-Tricine system) and 
immunoblotting [18-20]. For N-terminal amino acid sequencing, the 
Laemmli system was used since the difference of the resolution of 
C-terminal fragments between Laemmli system and Tris-tricine system 
was not seen. Antibodies to subsequences of APE 757 (Aft 1-10) and 
C-terminal R37 (residues 681-695 of APP-695), were produced as de- 
scribed previously [21]. Antiserum to Z31 (residues 577-596 of APP- 
695) was a gift from Dr. H. Yamaguchi. 
2.3. N-Terminal amino acM sequence analysis of C-terminal fragments 
Partially purified C-terminal fragments, derived from APE were 
separated by SDS-PAGE and then electroblotted onto a PVDF mem- 
brane [22]. The C-terminal fragment bands were cut out and applied 
on an automatic protein sequencer (Perkin Elmer 477A/120A). 
3. Results and discussion 
C-terminal fragments obtained from TB/T fraction had mo- 
lecular weights of 12-16 kDa (Laemmli system, as shown in 
Fig. 1) and 8-12 kDa (Tris-Tricine system, data not shown). 
These bands were labelled with anti-C-terminal R37 antibody 
and none of them were labelled with antiserum to Z31. The 
anti-757 antibody to Aft (1-10) appeared to react with at least 
two bands in the molecular weight range 15-16 kDa. A band 
at 16 kDa was the same molecular size as APPC-100 [23], as 
shown in Fig. 1. C-terminal fragment fractions were further 
separated by reverse phase HPLC [23] as shown in Fig. 1. The 
N-terminal amino acid sequences of each fraction are listed in 
Table 1 and summarized in Fig. 2. From this data it is clear that 
none of the sequenced bands are derived from APP-like mole- 
cules [24,25]. We were not able to determine N-terminal se- 
quences of other anti-R37 positive fractions because of contam- 
ination with other proteins and/or blocking of their N-termini. 
Previously, we reported that some secreted APP-695 in 
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Fig. 1. Immunoblots ofpartially purified C-terminal fragments of APP 
from DS brain. Lanes 1-7: anti-C-terminal R37 antibody; lanes 8 and 
9:anti-757 antibody. Lane 1, APP-C100 [23]; lane 2, crude C-terminal 
fragment of APP; lane 3 and 8, reverse-phase HPLC fr. 35, lane 4, fr. 
36; lane 5 and 9, fr. 37; lane 6, fr. 38; lane 7, fr. 39. Bands corresponding 
to identified N-terminal amino acid sequence are indicated by arrow- 
heads (35a and 35b from fraction 35, lane 3; 36a, b, and c from fraction 
36, lane 4; and 38 from fraction 38, lane 6, with 'a' being in each lane 
the uppermost arrowhead). 
human CSF and brain is produced by an alternative cleavage 
on the N-terminal side of Aft, and that this alternative cleavage 
would leave behind a membrane-bound fragment containing 
the whole of the Aft sequence, which could be further processed 
to release the amyloid peptide [7,8]. Seubert et al. have also 
reported that a substantial portion of the APP secreted by 
human mixed brain cell cultures, as well as that present in 
human CSF is of a novel form cleaved precisely at the amino 
terminus of Aft [ 17]. To confirm these results, we have analyzed 
the C-terminal fragments of APP in the membrane fraction of 
DS brain. 
We detected at least six different lengths of C-terminal frag- 
ment as shown Fig. 2. These results suggest hat the secretory 
processing of APP may be heterogenous in DS brain, although 
some effects of post-mortem proteolysis cannot be completely 
ruled out. However, similar results to ours have been reported 
recently by Zhong et al. and Cheung et al. [26,27] in culture 
cells, who noted cleavage of APP near the membrane surface 
at several different sites. Additionally, a C-terminal fragment 
starting at residue -30 (A/3 numbering) has been reported in 
Table 1 
Amino acid sequences of the C-terminal fragments derived from APP 
Yield of PTH-amino acid (pmol) 
Cycle 35a 35b 36a 36b 36c 38c 
1 X X X X X X 
2 S 1.48 K 1.33 V 1.28 Q 1.85 F 2.81 V 4.23 
3 E 2.56 M0.62 H 1.61 K 1.39 F 2.99 F 1.70 
4 V 1.02 D 0.92 H 1.87 L 0.67 A 4.76 F 2.48 
5 K 0.88 A 0.75 Q 1.27 V 1.08 E 1.28 A 4.93 
6 M 0.72 D 4.41 E 1.83 
7 D 1.64 V 1.60 D 3.90 
8 V 1.33 
9 G4.11 
10 S 1.48 
11 N 2.46 
12 K 1.32 
Unidentifiable r sidues are shown X. 
- -Z31  . . . . . .  ><- - -757- -> | < . . . . .  R37  . . . . .  > 
585 597 ~ 695 
APP N I KTEE I SEVKMDAEF RHDSG YEVHHQKLVFFAEDVGSNKGA . . . . . .  G YENPTYKFFEQMQN 
AI~ DAEFRHD $GYEVHHQKLVFFAEDVGSNKGA-  - 
1 3O 
3511 xSEVKMD- -  
35b  xKMDA- -  
36a  xVHHQ- -  
361) xQKLV- -  
36  c xFFAEDV-  - 
3 8 ×VFFAEDVGSNK- -  
Fig. 2. Summary of N-terminal amino acid sequences of C-terminal 
fragments derived from APP. Arrow indicates the cleavage site of 
'alpha-secretase' [9-11]. A~ consists of 3943 amino acid residues with 
ragged C-termini [21 .
lymphoblastoid cells obtained from patients with early-onset 
and late-onset familial AD, and in platelets of normal subjects 
[28,29]. 
Processing at -Glu-7-Ile -6 and -Glu-4-Va1-3 sites would gener- 
ate C-terminal fragments including the complete Aft sequence, 
with 3 or 6 additional amino acids (see Fig. 2). This would be 
compatible with our previous reports of secretory forms of APP 
in CSF [8] and brain [7] that appear to lack the Z31 sequence 
immediately prior to the amyloid region. Recently, it has been 
reported that N-terminal sequences of soluble Aft and the 
3 kDa product generated by subsequent processing of the non- 
amyloidogenic C-terminal fragment are heterogeneous 
[12,13,30-34]. The various N-terminal sequences described in 
these reports are comparable to the secretory processing sites 
of APP described here. Our results suggests that soluble Aft 
and the 3 kDa product are generated from C-terminal frag- 
ments after secretory processing. However, we cannot rule out 
the possibility that Aft is generated directly from intact APP via 
the lysosomal passway. Further extensive studies will be re- 
quired to clarify this point. 
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